Litcius/Paper detail

Efficacy and safety of stapokibart (CM310) in adults with moderate-to-severe atopic dermatitis: A multicenter, randomized, double-blind, placebo-controlled phase 3 trial

Yan Zhao, Litao Zhang, Jianzhong Zhang

2024Journal of the American Academy of Dermatology30 citationsDOIOpen Access PDF

Topics & Concepts

MedicineAtopic dermatitisPlaceboDouble blindRandomized controlled trialMulticenter studyDermatologyInternal medicineAlternative medicinePathologyDermatology and Skin DiseasesAllergic Rhinitis and SensitizationFood Allergy and Anaphylaxis Research
Efficacy and safety of stapokibart (CM310) in adults with moderate-to-severe atopic dermatitis: A multicenter, randomized, double-blind, placebo-controlled phase 3 trial | Litcius